{"schema_version":"1.0","type":"article","title":"出血少了，新藥為何還進不了美國？","url":"https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.md","lang":"zh-Hant","date":"2026-10-10","publish_at":"2026-10-10T08:00:00+08:00","updated_at":"2026-10-10","category":"商業分析系列","topic":"商業分析系列","tags":["Novo Nordisk","Mim8","denecimig","血友病","FDA"],"summary":"一款能讓血友病患者少出血的抗體，正卡在一個不會出現在療效曲線上的地方：工廠。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"臨床資料已發表、設施改善與美國FDA審查仍在進行的三個階段","url":"https://drugnews.com.tw/assets/articles/novo-mim8-manufacturing-fda-delay/FIG01_ZH_R1.png"},{"alt":"Mim8雙特異性抗體在活化血小板表面接住IXa與X，協助X活化成Xa的簡化機制","url":"https://drugnews.com.tw/assets/articles/novo-mim8-manufacturing-fda-delay/FIG02_ZH_R1.png"},{"alt":"FRONTIER2原先按需治療族群兩組的估計年化治療出血率15.76與0.20","url":"https://drugnews.com.tw/assets/articles/novo-mim8-manufacturing-fda-delay/FIG03_ZH_R1.png"},{"alt":"歐洲CHMP正面意見尚待執委會決定，美國FDA仍審查且尚無新決定時間的兩條時序","url":"https://drugnews.com.tw/assets/articles/novo-mim8-manufacturing-fda-delay/FIG04_ZH_R3.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/novo-mim8-manufacturing-fda-delay/FIG01_ZH_R1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-10）。出血少了，新藥為何還進不了美國？。https://drugnews.com.tw/articles/2026-10-10-novo-mim8-manufacturing-fda-delay.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-10-10-novo-mim8-manufacturing-fda-delay-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}